In addition, a previous study showed that sitagliptin potentially targeted the sympathetic nervous system, thus weakening the hypotensive effect of angiotensin-converting enzyme inhibitors (ACEI) in patients with metabolic syndrome [40]. Here, ACE is linked to metabolic syndrome.